Sonali Paul1, Asim Shuja2, Idy Tam3, Eun Min Kim3, Sandra Kang4, Leonid Kapulsky4, Kathleen Viveiros3, Hannah Lee5. 1. Division of Gastroenterology and Hepatology, Massachusetts General Hospital, 55 Fruit Street, Blake 4, Boston, MA, 02114, USA. sonali.paul2@gmail.com. 2. Department of Gastroenterology, University of Florida College of Medicine, 655 West 8th Street, Jacksonville, FL, 23309, USA. 3. Department of Gastroenterology and Hepatology, Tufts Medical Center, 800 Washington Street, Box #233, Boston, MA, 02111, USA. 4. Tufts University School of Medicine, 145 Harrison Street, Boston, MA, 02111, USA. 5. Division of Gastroenterology and Hepatology, Virginia Commonwealth University Medical Center, 1101 East Marshall Street, Richmond, VA, 23298-0663, USA.
Abstract
BACKGROUND AND AIMS: Hepatitis B reactivation in patients undergoing immunosuppressive therapy can lead to liver failure and death. Prior studies have shown suboptimal hepatitis B screening rates, but few have compared screening rates across specialties or factors associated with screening. METHODS: A retrospective study was performed using a hospital-based chemotherapy database and outpatient pharmacy records from January 1999 to December 2013. HBV screening rates prior to initiation of immunosuppression were determined. Multivariate analysis was used to determine predictors of HBV screening. RESULTS: Of the 4008 study patients, 47 % were screened prior to receiving immunosuppressive therapy; only 48 % on rituximab and 45 % of those on anti-TNF therapy were screened. Transplant specialists screened most frequently (85 %) while gastroenterologists screened the least (34 %). Factors significantly associated with HBV screening were younger age, Asian race, use of anti-rejection therapy, and treatment by a transplant specialist (p < 0.001). CONCLUSION: HBV screening prior to immunosuppressive therapy is suboptimal, especially among gastroenterologists. Efforts to improve screening rates in at risk populations are needed.
BACKGROUND AND AIMS: Hepatitis B reactivation in patients undergoing immunosuppressive therapy can lead to liver failure and death. Prior studies have shown suboptimal hepatitis B screening rates, but few have compared screening rates across specialties or factors associated with screening. METHODS: A retrospective study was performed using a hospital-based chemotherapy database and outpatient pharmacy records from January 1999 to December 2013. HBV screening rates prior to initiation of immunosuppression were determined. Multivariate analysis was used to determine predictors of HBV screening. RESULTS: Of the 4008 study patients, 47 % were screened prior to receiving immunosuppressive therapy; only 48 % on rituximab and 45 % of those on anti-TNF therapy were screened. Transplant specialists screened most frequently (85 %) while gastroenterologists screened the least (34 %). Factors significantly associated with HBV screening were younger age, Asian race, use of anti-rejection therapy, and treatment by a transplant specialist (p < 0.001). CONCLUSION:HBV screening prior to immunosuppressive therapy is suboptimal, especially among gastroenterologists. Efforts to improve screening rates in at risk populations are needed.
Authors: Rohit Loomba; Ayana Rowley; Robert Wesley; T Jake Liang; Jay H Hoofnagle; Frank Pucino; Gyorgy Csako Journal: Ann Intern Med Date: 2008-04-01 Impact factor: 25.391
Authors: Andrew S Artz; Mark R Somerfield; Jordan J Feld; Andrew F Giusti; Barnett S Kramer; Anita L Sabichi; Robin T Zon; Sandra L Wong Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Alissa Visram; Kelvin K W Chan; Phyllis McGee; Jordana Boro; Lisa K Hicks; Jordan J Feld Journal: PLoS One Date: 2015-04-15 Impact factor: 3.240
Authors: Eva C Schwaneck; Manuel Krone; Sonja Kreissl-Kemmer; Benedikt Weißbrich; Johannes Weiss; Hans-Peter Tony; Ottar Gadeholt; Marc Schmalzing; Andreas Geier Journal: Clin Rheumatol Date: 2018-09-20 Impact factor: 2.980
Authors: Sarah Patterson; Gabriela Schmajuk; Michael Evans; Ishita Aggarwal; Zara Izadi; Milena Gianfrancesco; Jinoos Yazdany Journal: Jt Comm J Qual Patient Saf Date: 2019-01-25
Authors: Gabriela Schmajuk; Chris Tonner; Laura Trupin; Jing Li; Urmimala Sarkar; Dana Ludwig; Stephen Shiboski; Marina Sirota; R Adams Dudley; Sara Murray; Jinoos Yazdany Journal: Medicine (Baltimore) Date: 2017-03 Impact factor: 1.889
Authors: Amir M Mohareb; Naomi J Patel; Xiaoqing Fu; Arthur Y Kim; Zachary S Wallace; Emily P Hyle Journal: J Rheumatol Date: 2021-08-01 Impact factor: 4.666